A Clinical Double Blind, Randomized Study of the Efficacy of Hyperuricemia Treatment With Anserine Product.
Status:
Unknown status
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Hyperuricemia is a common metabolic disorder.The Yaizu Suisankagaku Industry Company have
developed industrial production named Marine Active, was able to offer anti-fatigue activity
by animal trial data. Human clinical trials showed reduced creatine phosphokinase activity
and a sero-uric acid reduction activity was also observed. So we are committed to design the
clinical randomized, double blind study about hyperuricemia management with Marine Active.
All these efforts are hoped to find a novel method to manage hyperuricemia.